Ho-hum on head-to-head

Investors in Genmab A/S (CSE:GEN; OTCBB:GMXAY) appear to be placing little value on the company's lone marketed product, Arzerra ofatumumab. The company's stock ended in the black last week even though Arzerra was beaten in a head-to-head Phase III trial in its only marketed indication.

On Jan. 7, Pharmacyclics Inc. (NASDAQ:PCYC) stopped the Phase III RESONATE trial comparing its Imbruvica ibrutinib vs. Arzerra in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). An interim analysis showed Imbruvica was superior to Arzerra on the primary endpoint of progression-free survival (PFS) and the secondary endpoint of overall survival (OS). Detailed data were not disclosed...